NDC 63323-237-01 - CEFAZOLIN
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 63323-237
- Requested NDC
- 63323-237-01
- Package NDCs from labels
- 63323-237-01, 63323-237-10
- Manufacturer
- Fresenius Kabi USA, LLC | ACS Dobfar SpA
- Effective date
- 2023-09-27
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| CEFAZOLIN - Fresenius Kabi USA, LLC | ACS Dobfar SpA | Fresenius Kabi USA, LLC | ACS Dobfar SpA | 2023-09-27 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 63323-237-01 | CEFAZOLIN | 3 mL in 1 VIAL | POWDER, FOR SOLUTION | 3 | 8 | |
| 63323-237-10 | CEFAZOLIN | 25 in 1 CARTON | POWDER, FOR SOLUTION | 25 | 8 |
DailyMed Dashboard NDC Coverage#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 63323-237-10 | EA - Each | 63323-237 | 8ca6489e-d684-4f7b-a91f-23ede5a7fb1d | 1 | 2012-07-24 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| CEFAZOLIN SODIUM | ACTIVE INGREDIENT | P380M0454Z | CEFAZOLIN (CEFAZOLIN SODIUM) POWDER, FOR SOLUTION [FRESENIUS KABI USA, LLC] | 3 | |
| CEFAZOLIN | ACTIVE MOIETY | IHS69L0Y4T | CEFAZOLIN (CEFAZOLIN SODIUM) POWDER, FOR SOLUTION [FRESENIUS KABI USA, LLC] | 3 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Cefazolin | CEFAZOLIN | Hikma Pharmaceuticals USA Inc. | 06091653-e568-4e82-acc7-aefbce16de17 | 2024-04-18 | Warnings, Adverse reactions | P380M0454Z |
| Cefazolin | CEFAZOLIN | Qilu Pharmaceutical Co., Ltd. | e8bd9e95-8af5-416b-b58c-e1dbe3d052ac | 2023-12-18 | Warnings, Adverse reactions | 1665050 P380M0454Z |
| Cefazolin | CEFAZOLIN | Apotex Corp. | 37a626aa-96dc-4c4d-bfbc-be4f328f918b | 2023-12-15 | Warnings, Adverse reactions | 1665050 P380M0454Z |
| Cefazolin | CEFAZOLIN | Apotex Corp. | 0e8d4462-7642-4296-a605-6c1493e91ffd | 2023-12-14 | Warnings, Adverse reactions | P380M0454Z |
| Cefazolin | CEFAZOLIN | Apotex Corp. | 81d1783a-2baa-4d65-856a-f5ce38d24804 | 2023-12-14 | Warnings, Adverse reactions | P380M0454Z |
| CEFAZOLIN | CEFAZOLIN SODIUM | Fresenius Kabi USA, LLC | c47c8d14-1eef-40f9-9d11-f0c300b1d4be | 2023-09-27 | Warnings, Adverse reactions | ANDA065303 63323-236-10 63323-237-01 63323-237-10 63323-236-01 63323-237 63323-236 63323023701 1665052 1665050 321ffc80-ee94-4a86-8c33-e966438d9fbb c47c8d14-1eef-40f9-9d11-f0c300b1d4be P380M0454Z |
| Cefazolin | CEFAZOLIN | A-S Medication Solutions | 8a772acc-726d-40e6-88ee-b6075cbf9b28 | 2023-06-23 | Warnings, Adverse reactions | 1665050 P380M0454Z |
| Cefazolin | CEFAZOLIN | Medical Purchasing Solutions, LLC | 6673be13-4c74-70b9-e053-2a91aa0a211d | 2023-06-01 | Warnings, Adverse reactions | 1665050 P380M0454Z |
| Cefazolin | CEFAZOLIN | Medical Purchasing Solutions, LLC | 79787707-c84f-f229-e053-2a91aa0a1f16 | 2023-05-16 | Warnings, Adverse reactions | 1665050 P380M0454Z |
| Cefazolin | CEFAZOLIN | Proficient Rx LP | d24529e3-e2b4-46d6-81ba-b7da74501792 | 2022-08-01 | Warnings, Adverse reactions | 1665050 P380M0454Z |
| Cefazolin | CEFAZOLIN | Sandoz Inc | e58f87fb-a47d-4081-a454-e4e916e2f629 | 2020-09-08 | Warnings, Adverse reactions | P380M0454Z |
| Cefazolin | CEFAZOLIN SODIUM | Fresenius Kabi USA, LLC | 47a8928f-708d-418a-829b-36eded96bac0 | 2020-06-17 | Boxed warning, Warnings, Adverse reactions | P380M0454Z |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.